| ANIMAL | evidence | The influence of a novel pentadecapeptide, BPC 157, on N(G)-nitro-L-arginine methylester and L-arginine effects on stomach mucosa integrity and blood pressure. | BPC 157 | animal | 1997-07-30 |
| ANIMAL | evidence | The influence of BPC 157 on nitric oxide agonist and antagonist induced lesions in broiler chicks. | BPC 157 | Gut barrier & GI healing · animal | 1997-05-01 |
| ANIMAL | evidence | Pentadecapeptide BPC 157 positively affects both non-steroidal anti-inflammatory agent-induced gastrointestinal lesions and adjuvant arthritis in rats. | BPC 157 | Gut barrier & GI healing · animal | 1997-05-01 |
| ANIMAL | evidence | Pentadecapeptide BPC 157, cimetidine, ranitidine, bromocriptine, and atropine effect in cysteamine lesions in totally gastrectromized rats: a model for cytoprotective studies. | BPC 157 | Gut barrier & GI healing · animal | 1997-05-01 |
| ANIMAL | evidence | BPC 157's effect on healing. | BPC 157 | Skin appearance & aging · animal | 1997-05-01 |
| ANIMAL | evidence | Direct cellular effects of some mediators, hormones and growth factor-like agents on denervated (isolated) rat gastric mucosal cells. | BPC 157 | Longevity & cellular aging · animal | 1997-05-01 |
| ANIMAL | evidence | Pentadecapeptide BPC 157 interactions with adrenergic and dopaminergic systems in mucosal protection in stress. | BPC 157 | Gut barrier & GI healing · animal | 1997-03-01 |
| ANIMAL | evidence | Dose-dependent protective effect of BPC 157 on capsaicin-induced rhinitis in rats. | BPC 157 | animal | 1997-01-01 |
| ANIMAL | evidence | Beneficial effect of a novel pentadecapeptide BPC 157 on gastric lesions induced by restraint stress, ethanol, indomethacin, and capsaicin neurotoxicity. | BPC 157 | Gut barrier & GI healing · animal | 1996-08-01 |
| ANIMAL | evidence | Salutary and prophylactic effect of pentadecapeptide BPC 157 on acute pancreatitis and concomitant gastroduodenal lesions in rats. | BPC 157 | Gut barrier & GI healing · animal | 1996-07-01 |
| ANIMAL | evidence | BPC-15 reduces trinitrobenzene sulfonic acid-induced colonic damage in rats. | BPC 157 | Gut barrier & GI healing · animal | 1995-01-01 |
| ANIMAL | evidence | The beneficial effect of BPC 157, a 15 amino acid peptide BPC fragment, on gastric and duodenal lesions induced by restraint stress, cysteamine and 96% ethanol in rats. A comparative study with H2 receptor antagonists, dopamine promotors and gut peptides. | BPC 157 | Gut barrier & GI healing · animal | 1994-01-01 |
| ANIMAL | evidence | Hepatoprotective effect of BPC 157, a 15-amino acid peptide, on liver lesions induced by either restraint stress or bile duct and hepatic artery ligation or CCl4 administration. A comparative study with dopamine agonists and somatostatin. | BPC 157 | Liver health · animal | 1993-01-01 |
| ANIMAL | evidence | The significance of the gastroprotective effect of body protection compound (BPC): modulation by different procedures. | BPC 157 | animal | 1992-01-01 |
| PRECLINICAL | evidence | Rapid and harmonized analytical workflow for the determination of peptidic and non-peptidic doping agents in dried and liquid blood matrices. | BPC 157 | — | 2026-07-27 |
| PRECLINICAL | evidence | BPC-157 and Its Novel Hybrid Analogs as Inhibitors of Acetylcholinesterase. | BPC 157 | — | 2026-05-30 |
| PRECLINICAL | evidence | Unilateral Adrenalectomy, and the Stable Pentadecapeptide BPC 157 as Therapy in Rats-A Cytoprotection Approach. | BPC 157 | — | 2026-05-30 |
| PRECLINICAL | evidence | Protective effects of BPC 157 in rats with experimentally induced lower extremity ischemia-reperfusion injury. | BPC 157 | — | 2026-05-28 |
| PRECLINICAL | evidence | BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers. | BPC 157 | — | 2026-05-20 |
| PRECLINICAL | evidence | Endothelium-Dependent Nitric Oxide-Mediated Vasorelaxant Effects of BPC 157 in Human Internal Mammary Artery. | BPC 157 | — | 2026-05-02 |
| PRECLINICAL | evidence | Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives. | BPC 157 | — | 2026-04-27 |
| PRECLINICAL | evidence | Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. | BPC 157 | — | 2026-04-12 |
| PRECLINICAL | evidence | Peptide Therapies in Thyroid Health: Emerging Applications in Endocrine and Immune Modulation. | BPC 157 | — | 2026-04-01 |
| PRECLINICAL | evidence | From Regeneration to Analgesia: The Role of BPC-157 in Tissue Repair and Pain Management. | BPC 157 | Wound healing | 2026-03-22 |
| PRECLINICAL | evidence | Stable Gastric Pentadecapeptide BPC 157 as a Therapy of Severe Electrolyte Disturbances in Rats. | BPC 157 | — | 2026-03-13 |
| PRECLINICAL | evidence | Cytoprotection as a Unifying Strategy for Hemorrhage and Thrombosis: The Role of BPC 157 and Related Therapeutics. | BPC 157 | — | 2026-03-12 |
| PRECLINICAL | evidence | Tendon, Ligament, and Muscle Injury, Osteotendinous, Myotendinous, and Muscle-to-Bone Junction Therapy Perspectives with Growth Factors and Stable Gastric Pentadecapeptide BPC 157-A Review. | BPC 157 | — | 2026-02-12 |
| PRECLINICAL | evidence | Conventional Antiarrhythmics Class I-IV, Late INa Inhibitors, IKs Enhancers, RyR2 Stabilizers, Gap Junction Modulators, Atrial-Selective Antiarrhythmics, and Stable Gastric Pentadecapeptide BPC 157 as Useful Cytoprotective Therapy in Arrhythmias. | BPC 157 | — | 2026-01-29 |
| PRECLINICAL | evidence | BPC157 drives angiogenesis through FBXO22-dependent stabilization of BACH1. | BPC157 | — | 2026-01-29 |
| PRECLINICAL | evidence | Fourier Transform Infrared Spectroscopic Characterization of Aortic Wall Remodeling by Stable Gastric Pentadecapeptide BPC 157 After Unilateral Adrenalectomy in Rats. | BPC 157 | — | 2026-01-22 |
| PRECLINICAL | evidence | Tracheocutaneous Fistula Resolved by Pentadecapeptide BPC 157 Therapy Through the NO-System-Triple NO-Agent Approach in Rats. | BPC 157 | — | 2026-01-14 |
| PRECLINICAL | evidence | Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. | BPC 157 | — | 2026-01-01 |
| PRECLINICAL | evidence | Therapeutic peptides in gerontology: mechanisms and applications for healthy aging. | BPC 157 | — | 2026-01-01 |
| PRECLINICAL | evidence | Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions. | BPC 157 | Wound healing | 2026-01-01 |
| PRECLINICAL | evidence | Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. | BPC 157 | — | 2025-12-01 |
| PRECLINICAL | evidence | Challenge of Corneal Ulcer Healing: A Novel Conceptual Framework, the "Triad" of Corneal Ulcer Healing/Corneal Neovascularization/Intraocular Pressure, and Avascular Tendon Healing, for Evaluation of Corneal Ulcer Therapy, Therapy of Neovascularization, Glaucoma Therapy, and Pentadecapeptide BPC 157 Efficacy. | BPC 157 | — | 2025-11-28 |
| PRECLINICAL | evidence | BPC 157 Therapy: Targeting Angiogenesis and Nitric Oxide's Cytotoxic and Damaging Actions, but Maintaining, Promoting, or Recovering Their Essential Protective Functions. Comment on Jozwiak et al. Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review. Pharmaceuticals 2025, 18, 185. | BPC 157 | — | 2025-09-28 |
| PRECLINICAL | evidence | Reply to Sikiric et al. BPC 157 Therapy: Targeting Angiogenesis and Nitric Oxide's Cytotoxic and Damaging Actions, but Maintaining, Promoting, or Recovering Their Essential Protective Functions. Comment on "Jozwiak et al. Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review. Pharmaceuticals 2025, 18, 185". | BPC 157 | — | 2025-09-28 |
| PRECLINICAL | evidence | Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. | BPC 157 | — | 2025-09-01 |
| PRECLINICAL | evidence | Editorial Commentary: Testosterone, Growth Hormone, and Vitamin D Supplementation Is Not Routinely Indicated for Orthopaedic Surgery Patients. | BPC 157 | Growth hormone axis | 2025-08-01 |
| PRECLINICAL | evidence | Concerning BPC-157, a natural pentadecapeptide, that acts as a cytoprotectant and is believed to protect the gastro-intestinal tract (GIT). | BPC 157 | Gut barrier & GI healing | 2025-08-01 |
| PRECLINICAL | evidence | Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. | BPC 157 | — | 2025-07-31 |
| PRECLINICAL | evidence | Stable Gastric Pentadecapeptide BPC 157 as a Therapy and Safety Key: A Special Beneficial Pleiotropic Effect Controlling and Modulating Angiogenesis and the NO-System. | BPC 157 | — | 2025-06-19 |
| PRECLINICAL | evidence | Acute Compartment Syndrome and Intra-Abdominal Hypertension, Decompression, Current Pharmacotherapy, and Stable Gastric Pentadecapeptide BPC 157 Solution. | BPC 157 | — | 2025-06-10 |
| PRECLINICAL | evidence | Injectable Therapeutic Peptides-An Adjunct to Regenerative Medicine and Sports Performance? | BPC 157 | Exercise performance & endurance | 2025-02-01 |
| PRECLINICAL | evidence | Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review. | BPC 157 | — | 2025-01-30 |
| PRECLINICAL | evidence | Withdrawn: Stable Gastric Pentadecapeptide BPC 157 as a Therapy of Severe Electrolyte Disturbances in Rats. | BPC 157 | — | 2025-01-24 |
| PRECLINICAL | evidence | Stable Gastric Pentadecapeptide BPC 157 as Therapy After Surgical Detachment of the Quadriceps Muscle from Its Attachments for Muscle-to-Bone Reattachment in Rats. | BPC 157 | — | 2025-01-16 |
| PRECLINICAL | evidence | Compounded glucagon-like peptide-1 receptor agonists for weight loss: the direct-to-consumer market in Colorado. | BPC 157 | — | 2025-01-01 |
| PRECLINICAL | evidence | Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study. | BPC 157 | — | 2024-10-01 |